127 related articles for article (PubMed ID: 21536390)
21. Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure?
Li Z; Jin K; Lan H; Teng L
Hepatogastroenterology; 2011; 58(106):411-6. PubMed ID: 21661405
[TBL] [Abstract][Full Text] [Related]
22. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
[TBL] [Abstract][Full Text] [Related]
23. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.
Jiang Y; Mackley H; Cheng H; Ajani JA
Biomark Med; 2010 Aug; 4(4):535-41. PubMed ID: 20701442
[TBL] [Abstract][Full Text] [Related]
24. Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.
Chu E
Oncology (Williston Park); 2014 Feb; 28(2):96. PubMed ID: 24701695
[No Abstract] [Full Text] [Related]
25. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
26. Setting future standards for KRAS testing in colorectal cancer.
van Krieken H; Tol J
Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
[No Abstract] [Full Text] [Related]
27. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
[No Abstract] [Full Text] [Related]
28. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
[No Abstract] [Full Text] [Related]
29. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
[TBL] [Abstract][Full Text] [Related]
30. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
31. EGFR-targeted therapy.
Vecchione L; Jacobs B; Normanno N; Ciardiello F; Tejpar S
Exp Cell Res; 2011 Nov; 317(19):2765-71. PubMed ID: 21925171
[TBL] [Abstract][Full Text] [Related]
32. K-Ras mutation and prognosis of colorectal cancer: a meta-analysis.
Rui Y; Wang C; Zhou Z; Zhong X; Yu Y
Hepatogastroenterology; 2015; 62(137):19-24. PubMed ID: 25911860
[TBL] [Abstract][Full Text] [Related]
33. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
Nozawa K; Watanabe T
Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
[TBL] [Abstract][Full Text] [Related]
34. Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients.
Königsberg R; Hulla W; Klimpfinger M; Reiner-Concin A; Steininger T; Büchler W; Terkola R; Dittrich C
Oncology; 2011; 81(5-6):359-64. PubMed ID: 22248908
[TBL] [Abstract][Full Text] [Related]
35. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
37. Analysis of K-ras, BRAF, and PIK3CA mutations in laterally-spreading tumors of the colorectum.
Kaji E; Kato J; Suzuki H; Akita M; Horii J; Saito S; Higashi R; Ishikawa S; Kuriyama M; Hiraoka S; Uraoka T; Yamamoto K
J Gastroenterol Hepatol; 2011 Mar; 26(3):599-607. PubMed ID: 21332555
[TBL] [Abstract][Full Text] [Related]
38. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
[TBL] [Abstract][Full Text] [Related]
39. Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.
Kleist B; Kempa M; Meurer T; Poetsch M
J Clin Pathol; 2016 Mar; 69(3):204-8. PubMed ID: 26281864
[TBL] [Abstract][Full Text] [Related]
40. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
